Risk of Cardiovascular Disease Associated With Refractory Hypertension in Renal Transplant Recipients

被引:7
作者
Fernandez-Fresnedo, G. [1 ]
Gago-Fraile, M. [1 ]
Gomez-Alamillo, C. [1 ]
Sanz de Castro, S. [1 ]
Arias-Rodriguez, M. [1 ]
机构
[1] Hosp Univ Marques deValdecilla, Inst Formac & Invest Marques de Valdecilla, Serv Nephrol, Sanatander, Spain
关键词
OUTCOMES;
D O I
10.1016/j.transproceed.2010.07.042
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Hypertension is common after renal transplantation, affecting as many as 80% of recipients. It is generally accepted that hypertension is associated with poor graft survival and reduced life expectancy because of increased cardiovascular risk factors. The prevalence of refractory hypertension in renal transplant recipients is unknown, and could be associated with a poor prognosis. Objective. To investigate the effects of refractory hypertension on cardiovascular disease (CVD) after renal transplantation in 486 patients with grafts functioning for longer than 1 year. Patients and Methods. Patients were classified into 2 groups: (1) 57 with refractory hypertension, that is, systolic blood pressure 130 mm Hg or greater or diastolic blood pressure 80 mm Hg or greater, and receiving treatment with at least 3 drugs, one of which was a diuretic; and (2) the remaining 429 patients. Patient and graft survival, and posttransplantation CVD were analyzed. Results. Refractory hypertension was associated with male sex (82.5% vs 66.5% [P < .01]), poor renal function (mean [SD] serum creatinine concentration 2.2 [1.2] mg/dL vs 1.6 [0.6] mg/dL; Modification of Diet in Renal Disease score 39.2 [20.0] mL/min/1.73 m(2) vs 49.2 [18.0] mL/min/1.73 m(2) [P = .000]; and steroid therapy (94.7% vs 79.0% [P = .001]). In the group with refractory hypertension, 5-year patient and graft survival rates were lower, and the incidence of posttransplantation CVD was greater (relative risk, 1.7; 95% confidence interval, 1.05-2.18; P = .03). Conclusion. Refractory hypertension is an independent risk factor for increased cardiovascular morbidity and mortality in renal transplant recipients.
引用
收藏
页码:2908 / 2909
页数:2
相关论文
共 7 条
[1]   Response to about an epidemic of primary aldosteronism [J].
Calhoun, David A. .
HYPERTENSION, 2008, 51 (02) :E7-E7
[2]  
FERNANDEZFRESNE.G, 2006, TRANSPLANT REV, V20, P88
[3]   Clinical and Epidemiological Characteristics of Refractory Hypertension in Renal Transplant Patients [J].
Gago Fraile, M. ;
Fernandez Fresnedo, G. ;
Gomez-Alamillo, C. ;
Sanz de Castro, S. ;
Arias, M. .
TRANSPLANTATION PROCEEDINGS, 2009, 41 (06) :2132-2133
[4]   A practical guide to the management of hypertension in renal transplant recipients [J].
Olyaei, AJ ;
deMattos, AM ;
Bennett, WM .
DRUGS, 1999, 58 (06) :1011-1027
[5]   Improved long-term outcomes after renal transplantation associated with blood pressure control [J].
Opelz, G ;
Döhler, B .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (11) :2725-2731
[6]   Hypertension after renal transplantation [J].
Textor, S .
JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (12) :835-836
[7]   Hypertension, antihypertensive agents and outcomes following renal transplantation [J].
Tutone, VK ;
Mark, PB ;
Stewart, GA ;
Tan, CC ;
Rodger, RSC ;
Geddes, CC ;
Jardine, AG .
CLINICAL TRANSPLANTATION, 2005, 19 (02) :181-192